(Q34093408)

31 July 2017

1 reference

title

Clinically relevant differences between the statins: implications for therapeutic selection (English)

1 reference

31 July 2017

Chong PH

1 reference

31 July 2017

Seeger JD

series ordinal

1 reference

31 July 2017

Franklin C

series ordinal

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

American Journal of Medicine

31 July 2017

published in

1 reference

31 July 2017

volume

111

1 reference

31 July 2017

1 reference

31 July 2017

page(s)

390-400

1 reference

Drug treatment of lipid disorders

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

The evolving role of statins in the management of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Natural statins and stroke risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Statins: effective antiatherosclerotic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1,030 hypercholesterolemic patients. The Cerivastatin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Prospective evaluation of a stiff shaft glide wire compared with the standard straight wire in crossing severely stenotic aortic valves

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Maximizing the cost-effectiveness of lipid-lowering therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Lovastatin-associated sleep and mood disturbances

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Single-Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal Impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Clinically significant drug interactions with cyclosporin. An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

The interaction of diltiazem with lovastatin and pravastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Effect of itraconazole on the pharmacokinetics of atorvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Fluvastatin: a review of its use in lipid disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Current perspectives on statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Reductase inhibitor monotherapy and stroke prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

HMG-CoA reductase inhibitors and the risk of fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Invited commentary: low cholesterol and nonartherosclerotic disease risk: a persistently perplexing question

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Statins and the risk of dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

Primary prevention of coronary heart disease: integrating risk assessment with intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900870-1

10.1016/S0002-9343(01)00870-1

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference